美国黑人中血浆25-羟基维生素D与慢性肾脏病结局的效应修饰因素:杰克逊心脏研究
在5164名美国黑人前瞻性队列中,血浆25(OH)D平均为14.5±6.5 ng/mL;总体与eGFR下降无关,但在糖尿病患者中每升高5 ng/mL,eGFR下降减慢0.27 mL/min/1.73 m2/年(95%CI 0.13-0.41;P<0.001)。在DBP基因rs7041位点GG或GT基因型者中,每升高5 ng/mL与 incident CKD 风险降低相关(OR 0.69;95%CI 0.51-0.93;P-interaction=0.005)。
要点
- 美国黑人糖尿病患者中,较高25(OH)D与eGFR下降更慢相关。
- DBP基因rs7041位点GG或GT基因型者中,较高25(OH)D与CKD风险降低相关。
- 总体人群中25(OH)D与eGFR下降及CKD风险无显著关联。
核心结论
- 研究结果支持较高25(OH)D对合并糖尿病或特定DBP基因变异的美国黑人肾脏健康可能有潜在益处。
研究设计与样本
- 杰克逊心脏研究为美国黑人前瞻性队列,纳入5164名有25(OH)D数据的参与者,中位随访8年。
主要发现
- 血浆25(OH)D平均水平为14.5±6.5 ng/mL,eGFR平均水平为94.1±22.0 mL/min/1.73 m2。
- 在3228名完整数据参与者中,eGFR年下降为1.3±2.0 mL/min/1.73 m2;1803名合格参与者中220例发生新发CKD。
- 总体校正模型中25(OH)D与eGFR下降无关联;糖尿病患者中每升高5 ng/mL,eGFR下降减慢0.27 mL/min/1.73 m2/年(95%CI 0.13-0.41;P<0.001)。
- 总体25(OH)D与新发CKD无关联;DBP基因rs7041位点GG或GT基因型者中,每升高5 ng/mL,新发CKD的OR为0.69(95%CI 0.51-0.93;P-interaction=0.005)。
- 其他效应修饰因素(肥胖、膳食钠摄入、RAAS抑制剂使用)的交互作用不显著。
临床怎么用
- 对合并糖尿病的美国黑人,可关注25(OH)D水平与肾功能下降风险的关系。
- DBP基因rs7041位点GG或GT基因型可能提示较高25(OH)D与较低CKD风险相关,但尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 25-hydroxyvitamin D [25(OH)D] is lower in black compared with white Americans but is not consistently associated with outcomes in this group, possibly due to genetic and other biological differences. We examined the association of plasma 25(OH)D and renal outcomes in black Americans with a focus on effect modifiers. METHODS: We studied associations between baseline 25(OH)D with (i) annual rate of estimated glomerular filtration rate (eGFR) decline and (ii) incident chronic kidney disease (CKD) in the Jackson Heart Study, a prospective cohort of black Americans. Plasma 25(OH)D levels were corrected for monthly variation in sunlight exposure using the residual method. We used adjusted generalized linear models to evaluate outcomes and assessed potential effect modification by diabetes mellitus, vitamin D binding protein (DBP) genotype, obesity, dietary sodium intake, and use of renin-angiotensin-aldosterone system inhibitors. RESULTS: Among 5164 participants with 25(OH)D available, plasma 25(OH)D was 14.5 ± 6.5 ng/mL (mean ± SD), and eGFR was 94.1 ± 22.0 mL/min/1.73 m2. Over a median of 8 years, eGFR decline was 1.3 ± 2.0 mL/min/1.73 m2 per year in 3228 participants with complete data, and 220 out of 1803 eligible participants developed incident CKD. Overall, 25(OH)D was not associated with eGFR decline in fully adjusted models. However, higher 25(OH)D was associated with slower eGFR decline among those with diabetes: each 5 ng/mL higher 25(OH)D was associated with a 0.27 mL/min/1.73 m2/y slower eGFR decline (95% CI, 0.13 to 0.41; P < 0.001). Higher 25(OH)D was not associated with incident CKD overall, but it was associated with lower odds of incident CKD among participants with the GG or GT genotype at rs7041 in the gene encoding DBP [OR, 0.69 per 5 ng/mL higher 25(OH)D; 95% CI, 0.51 to 0.93; P-interaction = 0.005]. Other interactions were not significant. CONCLUSION: These findings support a potential benefit of higher 25(OH)D for kidney health in black Americans with diabetes or specific variants in DBP.
引用
- Lunyera J, Davenport CA, Pendergast J, et al. Modifiers of Plasma 25-Hydroxyvitamin D and Chronic Kidney Disease Outcomes in Black Americans: The Jackson Heart Study. J Clin Endocrinol Metab. 2019. PMID: 30668751. doi:10.1210/jc.2018-01747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。